Publication: One Health drivers of antibacterial resistance: Quantifying the relative impacts of human, animal and environmental use and transmission
5
Issued Date
2021-06-01
Resource Type
ISSN
23527714
Other identifier(s)
2-s2.0-85100821014
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
One Health. Vol.12, (2021)
Suggested Citation
Ross D. Booton, Aronrag Meeyai, Nour Alhusein, Henry Buller, Edward Feil, Helen Lambert, Skorn Mongkolsuk, Emma Pitchforth, Kristen K. Reyher, Walasinee Sakcamduang, Jutamaad Satayavivad, Andrew C. Singer, Luechai Sringernyuang, Visanu Thamlikitkul, Lucy Vass, Matthew B. Avison, Boonrat Chantong, Nisanart Charoenlap, Natacha Couto, Punyawee Dulyayangkul, Marjorie J. Gibbon, Virginia C. Gould, Varapon Montrivade, Kornrawan Phoonsawad, Nuchanart Rangkadilok, Parntep Ratanakorn, Kwanrawee Sirikanchana, Tawit Suriyo, Sarin Suwanpakdee, Katherine M.E. Turner, Kantima Wichuwaranan, Anuwat Wiratsudakul One Health drivers of antibacterial resistance: Quantifying the relative impacts of human, animal and environmental use and transmission. One Health. Vol.12, (2021). doi:10.1016/j.onehlt.2021.100220 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78181
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
One Health drivers of antibacterial resistance: Quantifying the relative impacts of human, animal and environmental use and transmission
Author(s)
Ross D. Booton
Aronrag Meeyai
Nour Alhusein
Henry Buller
Edward Feil
Helen Lambert
Skorn Mongkolsuk
Emma Pitchforth
Kristen K. Reyher
Walasinee Sakcamduang
Jutamaad Satayavivad
Andrew C. Singer
Luechai Sringernyuang
Visanu Thamlikitkul
Lucy Vass
Matthew B. Avison
Boonrat Chantong
Nisanart Charoenlap
Natacha Couto
Punyawee Dulyayangkul
Marjorie J. Gibbon
Virginia C. Gould
Varapon Montrivade
Kornrawan Phoonsawad
Nuchanart Rangkadilok
Parntep Ratanakorn
Kwanrawee Sirikanchana
Tawit Suriyo
Sarin Suwanpakdee
Katherine M.E. Turner
Kantima Wichuwaranan
Anuwat Wiratsudakul
Aronrag Meeyai
Nour Alhusein
Henry Buller
Edward Feil
Helen Lambert
Skorn Mongkolsuk
Emma Pitchforth
Kristen K. Reyher
Walasinee Sakcamduang
Jutamaad Satayavivad
Andrew C. Singer
Luechai Sringernyuang
Visanu Thamlikitkul
Lucy Vass
Matthew B. Avison
Boonrat Chantong
Nisanart Charoenlap
Natacha Couto
Punyawee Dulyayangkul
Marjorie J. Gibbon
Virginia C. Gould
Varapon Montrivade
Kornrawan Phoonsawad
Nuchanart Rangkadilok
Parntep Ratanakorn
Kwanrawee Sirikanchana
Tawit Suriyo
Sarin Suwanpakdee
Katherine M.E. Turner
Kantima Wichuwaranan
Anuwat Wiratsudakul
Other Contributor(s)
Chulabhorn Research Institute
Bristol Medical School
Bristol Veterinary School
London School of Hygiene & Tropical Medicine
University of Bath
University of Exeter
Chulabhorn Royal Academy
University of Bristol
Mahidol University
Faculty of Medicine Siriraj Hospital, Mahidol University
UK Centre for Ecology & Hydrology
Bristol Medical School
Bristol Veterinary School
London School of Hygiene & Tropical Medicine
University of Bath
University of Exeter
Chulabhorn Royal Academy
University of Bristol
Mahidol University
Faculty of Medicine Siriraj Hospital, Mahidol University
UK Centre for Ecology & Hydrology
Abstract
Objectives: Antibacterial resistance (ABR) is a major global health security threat, with a disproportionate burden on lower-and middle-income countries (LMICs). It is not understood how ‘One Health’, where human health is co-dependent on animal health and the environment, might impact the burden of ABR in LMICs. Thailand's 2017 “National Strategic Plan on Antimicrobial Resistance” (NSP-AMR) aims to reduce AMR morbidity by 50% through 20% reductions in human and 30% in animal antibacterial use (ABU). There is a need to understand the implications of such a plan within a One Health perspective. Methods: A model of ABU, gut colonisation with extended-spectrum beta-lactamase (ESBL)-producing bacteria and transmission was calibrated using estimates of the prevalence of ESBL-producing bacteria in Thailand. This model was used to project the reduction in human ABR over 20 years (2020–2040) for each One Health driver, including individual transmission rates between humans, animals and the environment, and to estimate the long-term impact of the NSP-AMR intervention. Results: The model predicts that human ABU was the most important factor in reducing the colonisation of humans with resistant bacteria (maximum 65.7–99.7% reduction). The NSP-AMR is projected to reduce human colonisation by 6.0–18.8%, with more ambitious targets (30% reductions in human ABU) increasing this to 8.5–24.9%. Conclusions: Our model provides a simple framework to explain the mechanisms underpinning ABR, suggesting that future interventions targeting the simultaneous reduction of transmission and ABU would help to control ABR more effectively in Thailand.